Haemophilia ANCT07653139
Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
An observational study of Haemophilia A, run by Novo Nordisk A/S at 1 site in Germany.
Trial summary
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Haemophilia A
- What is being tested?
- No treatment given
- How many people
- 150 participants
- Where
- 1 siteGermany
- Study dates
- 25 Sep 2026to 26 Dec 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with haemophilia A with and without inhibitors
Who may be able to join
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.
- Age above or equal to 18 years at the time of signing informed consent.
- Validated diagnose with haemophilia A, with and without inhibitors.
- Resident in Germany.
Who cannot join
- No provision of informed consent in this study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Age below 18 years at the time of signing informed consent.
- Absence of a diagnosis of haemophilia A.
- No residence in Germany.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.
- Conditions
- Haemophilia A
- Being tested
- No treatment given
- Medical subject headings
- Hemophilia A
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No treatment givenOther
Web-based survey
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | Adults with haemophilia A with and without inhibitors Receives: Other: No treatment given |
What is being measured
The primary outcome is the main question the study is designed to answer.
Choice of treatment alternative in discrete choice tasks
Categorical
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start25 Sep 2026
- Primary completion26 Dec 2026 (estimated)
- Study completion26 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Haemophilia AStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07653139
- Sponsor's protocol ID
- DAS-8858
- Other IDs
- U1111-1336-6966
- Status last verified
- Oct 2026
- First submitted
- 3 Jun 2026
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com